Fischer M, Denck H, Olbert F
Folia Haematol Int Mag Klin Morphol Blutforsch. 1979;106(5-6):938-45.
Thrombocytic therapy in peripheral arterial and venous vessel occlusion represents a clearly described alternative towards the surgery of vessels. A success rate of 36.5% can be found in subacute peripheral arterial thrombosis and 46.3% in subacute thrombotic occlusion of a bypass-graft. Contrary to that, a rate of 29.8% can be found in complications or side-effects respectively. In cases of peripheral deep venous thrombosis, a partial or full success can be found in 72%. However, the rate of complication amounting to 44.2% is comparatively high. The longer thrombolytic therapy with streptokinase or urokinase will last, the more frequently and more serious will be the complications, such as bleedings of different kind as well as increase of temperature to mention the most frequent ones. The application of urokinase is absolutely possible today, however, the use of urokinase seems to be only justified, if a thrombolytic therapy with streptokinase was carried out successfully and a subsequent surgical therapy was not possible. The present costs of this preparation are far too high for urokinase to be applied routinely. A thrombolytic therapy with SK as well as with UK has to be followed by an anticoagulant treatment.
外周动脉和静脉血管闭塞的血小板治疗是一种明确描述的血管手术替代方法。亚急性外周动脉血栓形成的成功率为36.5%，旁路移植血管亚急性血栓闭塞的成功率为46.3%。与此相反，并发症或副作用的发生率分别为29.8%。在外周深静脉血栓形成的病例中，72%可取得部分或完全成功。然而，并发症发生率达44.2%相对较高。使用链激酶或尿激酶进行溶栓治疗的时间越长，并发症就越频繁、越严重，如各种出血以及体温升高，这些是最常见的并发症。如今使用尿激酶绝对可行，然而，只有在成功进行链激酶溶栓治疗且随后无法进行手术治疗的情况下，使用尿激酶似乎才合理。这种制剂目前的成本过高，无法常规应用尿激酶。使用链激酶和尿激酶进行溶栓治疗后都必须进行抗凝治疗。
